MedTrace Logo

Safety, Tolerability and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

NCT03034135 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2021-09-13

Study results available
· View outcomes & findings →

Summary

This study of DSF-Cu in combination with TMZ for recurrent GBM will evaluate the antitumor effect in patients who have recurrent GBM. Patients will take DSF-Cu daily during their routine standard of care with TMZ therapy for approximately 6 months. Patients will be evaluated for response every 8 weeks. Patients will be followed up 2 years after the last dose of DSF-Cu.

Conditions

Interventions

DRUG

Disulfiram/Copper

Disulfiram/copper gluconate is taken three times a day.

DRUG

Temozolomide (TMZ)

TMZ is given per standard of care

Sponsors & Collaborators

  • Cantex Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Jiayi Huang, MD · Washington University School of Medicine in St. Louis

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-09
Primary Completion
2018-07-10
Completion
2018-07-10
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03034135 on ClinicalTrials.gov